Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

FBRX vs CELU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FBRX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–0 Matrix Metrics)

FBRX Overall Winner 6-Pillar Tally: FBRX 3 – 2 CELU (1 Tie) Matrix Metrics: FBRX 8 – 0 CELU

As of Nov 20, 2026, Forte Biosciences, Inc. (FBRX) is the stronger overall head-to-head candidate over Celularity Inc. (CELU) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). FBRX carries a Unified Composite Score of 52.7/100 (HOLD) at $76.99 (N/M Forward P/E, 0.0% operating margin), whereas CELU carries 42.9/100 (HOLD) at $0.46 (N/M Forward P/E, -254.0% operating margin).

  • Technical & Structure Timing Caution: FBRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.7); meanwhile CELU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FBRX vs CELU
FBRX NASDAQ Head-to-Head Winner
Forte Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$76.99
+0.03% 1D
Market Cap $1.6B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.09β · 3% Vol
Unified Composite Score
52.7 / 100 HOLD
Tech 49.0 Fund 51.0 Flow 62.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (78.3% over 20 days), RSI 85
RSI-14: 84.7 · SMA20: $76.83 · SMA50: $52.74
CELU NASDAQ
Celularity Inc. Class A Common Stock
Pharmaceutical Preparations
$0.46
-1.05% 1D
Market Cap $15.2M
TTM Revenue $19M
Forward P/E N/M
Beta / 30D Vol 2.01β · 135% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 25.0 Fund 48.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.3%), weak momentum, RSI 27
RSI-14: 26.9 · SMA20: $0.71 · SMA50: $1.08

6-Pillar Scorecard Institutional Category Breakdown (FBRX 3 – 2 CELU)

Columns: Metric · FBRX · CELU
1. Valuation Multiples CELU
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 2.7x
2. Growth & Scale FBRX
Revenue Growth (YoY) +0.0% -5.3%
Earnings Growth (YoY) +0.0% -61.3%
TTM Revenue (USD) N/A $19M
Market Cap $1.6B $15.2M
3. Profitability & Quality FBRX
Gross Margin N/A 19.2%
Operating Margin 0.0% -254.0%
Net Profit Margin 0.0% -245.7%
Return on Equity (ROE) -62.3% -6367.2%
4. Balance Sheet & Cash Flow CELU
Cash Generation (TTM) -$72M -$8.9M
Cash Flow Margin N/A -47.8%
Net Cash / Leverage $7.52 Book/Sh · -62.3% ROE $35M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning FBRX
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 11.1% (3rd %ile) 116.6% (50th %ile)
Put/Call OI Skew 0.77x (Call-Skewed) 3.60x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FBRX (8) vs CELU (0)
Institutional Metric FBRX CELU Criterion Row Edge
Market Capitalization
Scale
$1.6B $15.2M Larger Scale FBRX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -5.3% Higher Growth FBRX
Operating Margin (TTM)
Profitability
0.0% -254.0% Higher Margin FBRX
Net Profit Margin
Profitability
0.0% -245.7% Higher Margin FBRX
Return on Equity (ROE)
Capital Efficiency
-62.3% -6367.2% Higher ROE FBRX
52-Week Range Position
Momentum
100% ($10–$77) 2% ($0–$3) Stronger Trend FBRX
Beta / 30D Volatility
Risk Regime
1.09β · 3% Vol 2.01β · 135% Vol Lower Realized Risk FBRX
Unified Institutional Score
Composite Signal
52.7 / 100 (HOLD) 42.9 / 100 (HOLD) Higher Composite FBRX
Trailing 12M Revenue (USD)
Operating Scale
N/A $19M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 19.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 2.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$72M ($7.52 Book/Sh · -62.3% ROE) -$8.9M ($35M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CELU +15.39 pp
FBRX: +0.44% · CELU: +15.83%
3M Horizon FBRX +262.38 pp
FBRX: +258.59% · CELU: -3.79%
6M Horizon FBRX +200.28 pp
FBRX: +170.71% · CELU: -29.57%
1Y Horizon FBRX +359.4 pp
FBRX: +311.49% · CELU: -47.91%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period FBRX Revenue CELU Revenue FBRX Op. Margin CELU Op. Margin Margin Leader
FY2018 $20M N/A -254.2% N/A FBRX
FY2019 $0M N/A -11288.9% N/A FBRX
FY2020 N/A $10M N/A -1064.0% CELU
FY2021 N/A $20M N/A -511.2% CELU
FY2022 N/A $20M N/A -142.4% CELU
FY2023 N/A $20M N/A -844.4% CELU
FY2024 N/A $50M N/A -70.7% CELU
FY2025 N/A $30M N/A -230.9% CELU

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FBRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 11.1%
IV Percentile 3rd %ile
Put/Call OI Skew 0.77x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact FBRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CELU BREAKDOWN
60d in phase · OBV NEUTRAL
Current IV 116.6%
IV Percentile 50th %ile
Put/Call OI Skew 3.60x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CELU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FBRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.6B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CELU Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.2M market capitalization and -254.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FBRX vs CELU Key Questions & Quantitative Answers

As of Nov 20, 2026, Forte Biosciences, Inc. (FBRX) is the stronger overall head-to-head candidate over Celularity Inc. (CELU) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). FBRX carries a Unified Composite Score of 52.7/100 (HOLD) at $76.99 (N/M Forward P/E, 0.0% operating margin), whereas CELU carries 42.9/100 (HOLD) at $0.46 (N/M Forward P/E, -254.0% operating margin). Technical & Structure Timing Caution: FBRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.7); meanwhile CELU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FBRX leads the Growth & Scale pillar: FBRX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CELU at -5.3% YoY revenue growth and -61.3% YoY earnings growth on $19M TTM revenue (19.2% gross margin, -254.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), FBRX cumulative revenue shifted N/A while CELU shifted +200.0%. In operating R&D and SG&A reinvestment, FBRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CELU.

CELU screens cheaper on headline valuation multiples. FBRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CELU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.7x EV/Revenue (-47.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FBRX (-62.3% ROE) versus CELU (-6367.2% ROE) capital efficiency.

In options market volatility and institutional positioning, FBRX carries 11.1% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.09β · 3% Vol realized risk). By comparison, CELU carries 116.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), a 3.60x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 135% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.